Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -40.83M | -64.43M | -36.77M | -31.63M | -29.51M |
| Total Depreciation and Amortization | 76.00K | 97.00K | 99.00K | 99.00K | 133.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.69M | 4.87M | 3.26M | 4.59M | 3.41M |
| Change in Net Operating Assets | 2.22M | 12.48M | 2.86M | 3.05M | -1.66M |
| Cash from Operations | -28.86M | -46.98M | -30.56M | -23.89M | -27.63M |
| Capital Expenditure | -10.00K | -138.00K | -5.00K | -46.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.96M | 37.34M | -201.27M | 26.49M | 14.82M |
| Cash from Investing | -133.97M | 37.20M | -201.28M | 26.45M | 14.79M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 740.75M | 5.08M | 274.69M | 568.00K | 161.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.34M | -192.00K | -172.00K | -- | -- |
| Cash from Financing | 739.41M | 4.88M | 274.51M | 568.00K | 161.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 576.58M | -4.90M | 42.68M | 3.12M | -12.68M |